What Takeda Canada does

Takeda Canada Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a Japanese-headquartered multinational pharmaceutical company founded in 1781 and publicly traded on the Tokyo Stock Exchange (TSE:4502) and NYSE (NYSE:TAK). Operating from Toronto with 1001-5000 employees in Canada, the subsidiary commercializes Takeda's specialty pharmaceutical portfolio across six core therapeutic areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Key Canadian-commercialized products include FRUZAQLA (fruquintinib), a VEGF receptor inhibitor for metastatic colorectal cancer that received Health Canada market authorization in September 2024 and is now reimbursed in at least seven Canadian provinces including Ontario and British Columbia.

The company's underlying technology is rooted in proprietary small-molecule and biologic drug development, with differentiated pipeline assets including zasocitinib (TAK-279), a next-generation oral TYK2 inhibitor with >1-million-fold selectivity versus other JAK enzymes, and oveporexton (TAK-861), an orexin receptor 2-selective agonist for narcolepsy type 1 that received FDA Priority Review with a Q3 2026 PDUFA goal date. Takeda's dengue vaccine, with seven years of protection demonstrated in Phase 3 trials across 20,000+ participants in Latin America and Asia, is projected to reach approximately $1.6 billion in annual sales by 2030. The parent employs staff across approximately 80 countries and operates manufacturing facilities including the Singen site in Germany.

Takeda's revenue model is based on one-time prescription pharmaceutical product sales distributed through direct sales to healthcare institutions, pharmacy distribution networks, and government reimbursement programs including provincial exceptional access programs in Canada. Go-to-market is sales-led, executed through pharmaceutical sales representatives promoting approved drugs to healthcare providers and institutional buyers. The company is led by newly appointed President and CEO Julie Kim (effective June 2026), succeeding Christophe Weber after 12 years. The business is highly dependent on regulatory approvals and payer reimbursement decisions; Canadian revenue concentration in provincial government payers creates moderate concentration risk offset by prescriber-level distribution across hospitals, clinics, and pharmacies.

Name

Takeda Canada

Legal name

Takeda Pharmaceutical Company Limited

Website

https://takeda.com

Company type

Public

Founded year

1781

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Specialty pharmaceuticals
• Oncology therapeutics
• Rare disease treatments
• Plasma-derived therapies
• Vaccines and biologics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Takeda generates revenue primarily through the sale of prescription pharmaceutical products across its core therapeutic areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Products are sold through various channels including direct sales to healthcare providers and institutional buyers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Takeda Canada is the Canadian subsidiary of Takeda Pharmaceutical Company Limited, focused on developing, manufacturing, and commercializing specialty prescription medicines for gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company markets approved products such as FRUZAQLA (fruquintinib) for metastatic colorectal cancer and is advancing late-stage pipeline assets including zasocitinib (TAK-279) for plaque psoriasis and oveporexton (TAK-861) for narcolepsy type 1.

Differentiator

Problem solved

Functional benefit

Brands

• FRUZAQLA (fruquintinib capsules): A treatment for metastatic colorectal cancer (mCRC) that received Health Canada market authorization in September 2024 and is reimbursed in multiple Canadian provinces.

Products and services

• FRUZAQLA (fruquintinib capsules) Oral VEGF receptor inhibitor (fruquintinib capsules) for the treatment of adult patients with metastatic colorectal cancer who have exhausted standard therapy options; reimbursed in multiple Canadian provinces through government exceptional access programs.

Quantifiable outcome

• Approximately 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 with zasocitinib in Phase 3 plaque psoriasis studies
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Denali TherapeuticsminorStrategic or Co-development Partner · 5 April 2026Takeda previously collaborated with Denali Therapeutics to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN). Takeda terminated the collaboration agreement driven by strategic considerations unrelated to safety or efficacy. Denali will regain full control of DNL593 and its intellectual property portfolio.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pfizer: Global R&D-driven pharmaceutical company with comparable scale, multi-therapeutic-area pipeline (oncology, immunology, vaccines, neuroscience), and similar global commercial footprint across ~80+ countries; competes directly with Takeda in oncology, vaccines, and rare diseases.
• Roche: Major oncology and immunology-focused pharmaceutical company with comparable R&D scale and therapeutic-area overlap; competes with Takeda in colorectal cancer (FRUZAQLA competes with bevacizumab-based regimens) and immunology.
• AbbVie: Leader in immunology (Humira/Skyrizi/Rinvoq) directly competing with Takeda's TYK2 franchise; AbbVie's neuroscience and oncology pipelines overlap with Takeda's, and both pursue branded-innovator commercial strategies post-major acquisitions.
• AstraZeneca: Oncology and rare-disease focused pharmaceutical company with comparable global commercial reach; competes with Takeda in colorectal cancer and increasingly in immunology, with similar innovator-pharma business model.
• Novartis: Swiss multinational with overlapping franchises in oncology, immunology, and neuroscience; competes with Takeda in specialty therapeutics and shares the innovator-branded pharmaceutical business model with similar pipeline depth and global commercialization capabilities.
• Merck & Co. Key oncology competitor with overlapping solid-tumor pipeline and global launch capabilities; Merck's vaccine franchise (including pneumococcal and pipeline assets) competes with Takeda's dengue vaccine, while oncology overlap extends to colorectal cancer.
• Sanofi: European multinational with strong rare-disease and immunology franchises overlapping Takeda's post-Shire portfolio; comparable scale, multi-area pipeline, and global commercialization including in Canadian provincial reimbursement markets.
• GSK: Global pharmaceutical company with strong vaccine franchise directly overlapping Takeda's dengue vaccine ambitions; also competes in oncology and immunology with similar innovator-pharma commercial model and global distribution.
• Bristol-Myers Squibb: Direct oncology and immunology competitor with overlapping pipelines in solid tumors and inflammatory diseases; both companies emphasize branded innovator pharmaceuticals and operate similar global commercial models.

Broad incumbents

• Johnson & Johnson Innovative Medicine: Diversified pharmaceutical incumbent with oncology, immunology, and neuroscience franchises overlapping Takeda's core therapeutic areas; broader portfolio (medical devices, consumer) but operates as a comparable large-cap branded pharmaceutical peer in similar global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/takeda-pharmaceuticals
• LinkedInlinkedin.com/company/takeda-canada-inc-
• Xx.com/TakedaPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Takeda Canada